International Journal of Infectious Diseases
Volume 14, Issue 8 , Pages e649-e658 , August 2010

Pediatric disease burden and vaccination recommendations: understanding local differences

  • Angela Gentile

      Affiliations

    • Ricardo Guiterrez Children's Hospital, Gallo 1330 (1425) Buenos Aires, Argentina
    • Corresponding Author InformationCorresponding author. Tel./fax: +54 11 4964 9019.
    • ,
  • Zulfiqar Bhutta

      Affiliations

    • Aga Khan University, Karachi, Pakistan
    • ,
  • Lulu Bravo

      Affiliations

    • University of the Philippines, Manila, Philippines
    • ,
  • Aly Gamal Samy

      Affiliations

    • Ain Shams University, Cairo, Egypt
    • ,
  • R. Dennis J. Garcia

      Affiliations

    • Makati Medical Center, Makati, Philippines
    • ,
  • Anwar Hoosen

      Affiliations

    • University of Pretoria, South Africa
    • ,
  • Tazul Islam

      Affiliations

    • EPI Mohakhali, Dhaka, Bangladesh
    • ,
  • Abdollah Karimi

      Affiliations

    • Research Center of Pediatric Infectious Diseases, Beheshti University, Mofid Hospital, Tehran, Iran
    • ,
  • Mona Salem

      Affiliations

    • Ain Shams University, Cairo, Egypt
    • ,
  • Sriluck Simasathien

      Affiliations

    • Pediatric Infectious Diseases Society of Thailand, Bangkok, Thailand
    • ,
  • Amir Sohail

      Affiliations

    • 22/20 B Khiljee Road, Block-B, Mohammadpur, Dhaka-1207, Bangladesh
    • ,
  • Veerachai Watanaveeradej

      Affiliations

    • Phramongkutklao Hospital, Bangkok, Thailand
    • ,
  • Karin Wiedenmayer

      Affiliations

    • Swiss Tropical Institute, Basel, Switzerland
    • ,
  • Heinz-J. Schmitt

      Affiliations

    • Novartis Vaccines and Diagnostics GmbH & Co. KG, Marburg, Germany

Received 16 April 2009 ,Revised 26 August 2009 ,Accepted 5 November 2009.

References 

  1. Centers for Disease Control and Prevention (CDC). Epidemiology and prevention of vaccine-preventable diseases [Diphtheria]. 10th ed. Washington, DC: Public Health Foundation; 2008:pp. 50–70. Available at: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/dip.pdf (accessed April 1, 2009).
  2. World Health Organization (WHO). Immunization surveillance, assessment and monitoring. Diphtheria. Geneva: WHO; 2010. Available at: http://www.who.int/immunization_monitoring/diseases/diphteria/en/index.html (accessed February 10 2010).
  3. Bleck TP. Clostridium tetani (Tetanus). In:  Mandell GL,  Bennett JE,  Dolin R editor. Principles and practice of infectious diseases. 6th ed.. Philadelphia, USA: Churchill Livingstone; 2005;p. 2817–2822
  4. Centers for Disease Control and Prevention (CDC). Epidemiology and prevention of vaccine-preventable diseases [Tetanus]. 10th ed. Washington, DC: Public Health Foundation; 2008 pp. 273–282. Available at: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/tetanus.pdf (accessed February 10, 2010).
  5. World Health Organization (WHO). Immunization surveillance, assessment and monitoring. Tetanus. Geneva: WHO; 2010. Available at: http://www.who.int/immunization_monitoring/diseases/tetanus/en/index.html (accessed February 10, 2009).
  6. World Health Organization (WHO). Pertussis vaccines. WHO position paper. Wkly Epidemiol Rec 2005;80:29–40.
  7. World Health Organization (WHO). Immunization surveillance, assessment and monitoring. Pertussis. Geneva: WHO; 2010. Available at: http://www.who.int/immunization_monitoring/diseases/pertussis/en/index.html (accessed February 10, 2010).
  8. World Health Organization (WHO). Hepatitis B vaccines. WHO position paper. Wkly Epidemiol Rec 2004;79:255–63.
  9. World Health Organization (WHO). Immunization surveillance, assessment and monitoring. Hepatitis B. Geneva: WHO; 2010. Available at: http://www.who.int/immunization_monitoring/diseases/hepatitis/en/index.html (accessed February 10, 2010).
  10. World Health Organization (WHO). Hepatitis B. Fact sheet No. 204. Geneva: WHO; 2008. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/index.html (accessed February 10, 2010).
  11. World Health Organization (WHO). Haemophilus influenzae type B (Hib). Fact sheet No. 294. Geneva: WHO; 2005. Available at: http://www.who.int/mediacentre/factsheets/fs294/en/index.html (accessed April 1, 2009).
  12. World Health Organization (WHO). WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 2006; 81:445–52.
  13. World Health Organization (WHO). Measles. Fact sheet No. 286. Geneva: WHO; 2009. Available at: http://www.who.int/mediacentre/factsheets/fs286/en/index.html (accessed February 10, 2010).
  14. World Health Organization (WHO). Immunization surveillance, assessment and monitoring. Measles. Geneva: WHO; 2010. Available at: http://www.who.int/immunization_monitoring/diseases/measles/en/index.html. (accessed February 10, 2010).
  15. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2000;13:302–317
  16. Lattanzi M, Rappuoli R. Novel vaccination strategies. In:  Kaufmann SH,  Lambert PH editor. The grand challenge for the future. Basel, Switzerland: Birkhäuser Verlag; 2005;p. 77–98
  17. Global Polio Eradication Initiative (GPEI). Background: The history. Available at: http://www.polioeradication.org/history.asp (accessed April 1, 2009).
  18. World Health Organization (WHO). WHO position paper on diphtheria. Wkly Epidemiol Rec 2006;81:21–32.
  19. World Health Organization (WHO). WHO position paper on tetanus. Wkly Epidemiol Rec 2006;81:197–208.
  20. World Health Organization (WHO). WHO position paper on measles. Wkly Epidemiol Rec 2006;79:129–44.
  21. World Health Organization (WHO). Immunization against diseases of public health importance. Fact sheet No. 288. Geneva: WHO; 2005. Available at: http://www.who.int/mediacentre/factsheets/fs288/en/index.html (accessed April 1, 2009).
  22. GAVI Alliance. Immunisation. Geneva: GAVI; 2006. Available at: http://www.gavialliance.org/resources/FS_Immunisation_Aug06_en.pdf (accessed April 1, 2009).
  23. Wiedenmayer KA, Weiss S, Chattopadhyay C, Mukherjee A, Kundu R, Ayé R, et al. Simplifying paediatric immunization with a fully liquid DTP–HepB–Hib combination vaccine: evidence from a comparative time-motion study in India. Vaccine. 2009;27:655–659
  24. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25:507–512
  25. Bloom DE, Canning D, Weston M. The value of vaccination. World Economics. 2005;6:15–39
  26. World Health Organization (WHO). Estimated annual incidence for selected causes: by sex, age and WHO subregion, 2002. World health report 2004. Geneva: WHO; 2004. Available at: http://www.who.int/healthinfo/statistics/gbdwhoregionincidence2002.xls (accessed April 1, 2009).
  27. World Health Organization (WHO). Global and regional immunization profile. African Region. Geneva: WHO; 2008. Available at: http://www.who.int/immunization_monitoring/en/globalsummary/GS_AFRProfile.pdf (accessed April 1, 2009).
  28. World Health Organization (WHO). Global and regional immunization profile. Region of the Americas. Geneva: WHO; 2008. Available at: http://www.who.int/immunization_monitoring/en/globalsummary/GS_AMRProfile.pdf (accessed April 1, 2009).
  29. World Health Organization (WHO). Global and regional immunization profile. Eastern Mediterranean Region. Geneva: WHO; 2008. Available at: http://www.who.int/immunization_monitoring/en/globalsummary/GS_EMRProfile.pdf (accessed April 1, 2009).
  30. World Health Organization (WHO). Global and regional immunization profile. European Region. Geneva: WHO; 2008. Available at: http://www.who.int/immunization_monitoring/en/globalsummary/GS_EURProfile.pdf (accessed April 1, 2009).
  31. World Health Organization (WHO). Global and regional immunization profile. South-East Asia Region. Geneva: WHO; 2008. Available at: http://www.who.int/immunization_monitoring/en/globalsummary/GS_SEAProfile.pdf (accessed April 1, 2009).
  32. World Health Organization (WHO). Global and regional immunization profile. Western Pacific Region. Geneva: WHO; 2008. Available at: http://www.who.int/immunization_monitoring/en/globalsummary/GS_WPRProfile.pdf (accessed April 1, 2009).
  33. World Health Organization (WHO). WHO vaccine preventable diseases monitoring system. 2008 Global summary. Geneva: WHO; 2008. Available at: http://www.who.int/vaccines/globalsummary/immunization/countryprofileselect.cfm (accessed April 1, 2009).
  34. World Health Organization (WHO). WHO vaccine-preventable diseases: monitoring system. 2007 global summary. Geneva: WHO; 2007. Available at: http://www.who.int/immunization/documents/WHO_IVB_2007/en/index.html (accessed April 1, 2009).
  35. World Health Organization (WHO) . WHO position paper on pneumococcal conjugate vaccine for childhood immunization. Wkly Epidemiol Rec. 2006;82:93–104
  36. Republic of South Africa Department of Health. Statistical notes. South Africa: Department of Health; 2005. Available at: http://www.doh.gov.za/facts/stats-notes/2005/hepb.pdf (accessed April 1, 2009).
  37. Boletín epidemiológico anual. Ministro de salud de la nacion, Argentina. 2006. Inmunoprevinibles. Available at: http://www.msal.gov.ar/htm/Site/sala_situacion/PANELES/boletines/bepAnual/BEPanual2006_Inmunoprev.pdf (accessed December 1, 2008).
  38. Ali SA, Donahue RM, Qureshi H, Vermund SH. Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. Int J Infect Dis. 2009;13:9–19
  39. Nizami SQ, Bhutta ZA, Hasan R. Incidence of acute respiratory infections in children 2 months to 5 years of age in periurban communities in Karachi. Pakistan. J Pak Med Assoc. 2006;56:163–167
  40. Ministry of Health, Saudi Arabia. Statistics year book 2006. A review of health situation. Saudi Arabia: Ministry of Health; 2006. Available at: http://www.moh.gov.sa/statistics/S1427/Chapter%201.pdf (accessed April 1, 2009).
  41. Liver Foundation of Bangladesh. Hepatitis B. Bangladesh: Liver Foundation; 2006. Available at: http://www.liver.org.bd/Hepatitis-B.asp?SP=LM&VW=1 (accessed April 1, 2009).
  42. Rerks-Ngarm S, Treleaven SC, Chunsuttiwat S, Muangchana C, Jolley D, Brooks A, et al. Prospective population-based incidence of Haemophilus influenzae type b meningitis in Thailand. Vaccine. 2004;22:975–983
  43. Bureau of Epidemiology, Thailand. Annual epidemiological surveillance report 2007. Thailand: Ministry of Health; 2007. Available at: http://epid.moph.go.th (accessed September 1, 2008).
  44. Limcangco MR, Salole EG, Armour CL. Epidemiology of Haemophilus influenzae type b meningitis in Manila, Philippines, 1994 to 1996. Pediatr Infect Dis J. 2000;19:7–11
  45. Redwan el-RM , Elsawy A. Surveillance of natural acquired antibodies to Haemophilus influenzae type b among children in Cairo-Egyptian. Hum Antibodies. 2005;14:23–26
  46. Lansang MA. Epidemiology and control of hepatitis B infection: a perspective from the Philippines. Asia. Gut. 1996;38(Suppl 2):S43–S47
  47. Bhutta ZA. Burden of Haemophilus influenzae and Streptococcus pneumoniae infections during childhood in Pakistan. J Coll Physicians Surg Pak. 2000;10:346–354
  48. Quddus A, Luby S, Rahbar M, Pervaiz Y. Neonatal tetanus: mortality rate and risk factors in Loralai District. Pakistan. Int J Epidemiol. 2002;31:648–653
  49. World Health Organization (WHO). Catalogue of immunization policy recommendations [pertussis, diphtheria, and measles]. Geneva: WHO; 2008. Available at: http://www.who.int/immunization/policy/en/ (accessed April 1, 2009).
  50. Murphy TV, Slade BA, Broder KR, Kretsinger K, Tiwari T, Joyce PM, et al. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-4):1–51
  51. UNdata. Neonates protected at birth against neonatal tetanus. Philippines 2006. United Nations Statistics Division; 2008. Available at: http://data.un.org/Data.aspx?d=WHO&f=inID%3AHSC04 (accessed April 1, 2009).
  52. Corrigall J, Coetzee D, Cameron N. Is the Western Cape at risk of an outbreak of preventable childhood diseases? Lessons from an evaluation of routine immunisation coverage. S Afr Med J. 2008;98:41–45
  53. Siedler A, Tischer A, Mankertz A, Santibanez S. Two outbreaks of measles in Germany 2005. Euro Surveill. 2006;11:131–134
  54. Richard JL, Spicher VM. Ongoing measles outbreak in Switzerland: results from November 2006 to July 2007. Euro Surveill. 2007;12:1;E070726
  55. Schmid D, Holzmann H, Abele S, Kasper S, König S, Meusburger S, et al. An ongoing multi-state outbreak of measles linked to non-immune anthroposophic communities in Austria, Germany, and Norway, March–April 2008. Euro Surveill. 2008;13:1–2
  56. Parker AA, Staggs W, Dayan GH, Ortega-Sánchez IR, Rota PA, Lowe L, et al. Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. N Engl J Med. 2006;355:447–455
  57. Pearce A, Law C, Elliman D, Cole TJ Bedford H; Millennium Cohort Study Child Health Group. Factors associated with uptake of measles, mumps, and rubella vaccine (MMR) and use of single antigen vaccines in a contemporary UK cohort: prospective cohort study. BMJ. 2008;336:754–757
  58. World Health Organization (WHO) Vaccine Preventable Diseases Monitoring System. Immunization schedules by antigen. Geneva: WHO; 2009. Available at: http://www.who.int/immunization_monitoring/data/schedule_data.xls (accessed April 1, April 2009).
  59. World Health Organization (WHO). WHO/UNICEF Regional Child Survival Strategy: accelerated and sustained action towards MDG 4. Geneva: WHO; 2006. Available at: http://www.wpro.who.int/NR/rdonlyres/BAA52CCD-88B6-4D8B-9BC8-F9F64C963213/0/FinalRegionalChildSurvivalStrategy.pdf (accessed April 1, 2009).
  60. Adegbola RA, Secka O, Lahai G, Lloyd-Evans N, Njie A, Usen S, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet. 2005;366:144–150
  61. Lewis RF, Kisakye A, Gessner BD, Duku C, Odipio JB, Iriso R, et al. Action for child survival: elimination of Haemophilus influenzae type b meningitis in Uganda. Bull World Health Organ. 2008;86:292–301
  62. Lim SS, Stein DB, Charrow A, Murray CJ. Tracking progress towards universal childhood immunisation and the impact of global initiatives: a systematic analysis of three-dose diphtheria, tetanus, and pertussis immunisation coverage. Lancet. 2008;372:2031–2046
  63. Gellin BG, Maibach EW, Marcuse EK. Do parents understand immunizations? A national telephone survey. Pediatrics. 2000;106:1097–1102
  64. Decker MD, Edwards KM, Bogaerts HH. Combination vaccines. In:  Plotkin SA,  Orenstein WA,  Offit PA editor. Vaccines. 5th ed.. Philadelphia, USA: Saunders; 2008;p. 1069–1101
  65. Lugo NR, Montoya C, Koslap-Petraco MB. Parents’ perspectives on immunizations: a survey. American Journal for Nurse Practitioners. 2003;7:8–19
  66. Kanra G, Kara A, Demiralp O, Contorni M, Hilbert AK, Spyr C, et al. Safety and immunogenicity of a new fully liquid DTPw–HepB–Hib combination vaccine in infants. Hum Vaccin. 2006;2:155–160
  67. Blatter MM, Reisinger KS, Terwelp DR, DelBuono FJ, Howe BJ. Immunogenicity of a combined diphtheria–tetanus–acellular pertussis (DT–tricomponent Pa)–hepatitis B (HB)–inactivated poliovirus (IPV) admixed with Haemophilus influenzae type b (Hib) vaccine in infants. The American Pediatric Society and the Society for Pediatric Research meeting, May 1-5, 1998, New Orleans, USA. Pediatr Res 1998;43(4 part 2):141A. [abstract].
  68. Arístegui J, Dal-Ré R, Díez-Delgado J, Marés J, Casanovas JM, García-Corbeira P, et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa–HBV–IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa–IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine. 2003;21:3593–3600
  69. Black S, Nakasato C, Davis R, France E, Schuerman L, Jacquet JM, et al. Two large phase III, multicenter trials comparing primary vaccination with DTPa–HBV–IPV/Hib versus commercially available vaccines administered at separate sites. Poster presentation. 4th World Congress of the World Society for Pediatric Infectious Diseases (WSPID), September 1-4, 2005, Warsaw, Poland.
  70. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet. 1997;350:1569–1577
  71. Southern J, McVernon J, Gelb D, Andrews N, Morris R, Crowley-Luke A, et al. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. Clin Vaccine Immunol. 2007;14:1328–1333
  72. Rieber N, Graf A, Belohradsky BH, Hartl D, Urschel S, Riffelmann M, et al. Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination. Vaccine. 2008;26:6929–6935
  73. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine. 2003;21:2003–2014
  74. International Finance Facility for Immunisation (IFFIm). Update 3: June 2008. Available at: http://www.iff-immunisation.org/pdfs/update3_3GBweb.pdf (accessed April 1, 2009).
  75. GAVI Alliance. GAVI Alliance progress report 2007. Geneva: GAVI; 2007. Available at: http://www.gavialliance.org/resources/2007GAVIreport.pdf (accessed April 1, 2009).
  76. World Health Organization (WHO). Global immunization news (GIN). Geneva: WHO; 2007. Available at: http://www.who.int/immunization/GIN_October2007.pdf (Accessed 1st April 2009).

☆ The information given here was presented at the Quinvaxem Advisory Board meeting at the 13th International Congress on Infectious Diseases, Kuala Lumpur, Malaysia, June 19, 2008.

PII: S1201-9712(10)00017-2

doi: 10.1016/j.ijid.2009.11.006

International Journal of Infectious Diseases
Volume 14, Issue 8 , Pages e649-e658 , August 2010

Article Tools

* Image Usage & Resolution